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Modified Vaccinia virus Ankara (MVA)

Gwendal Gränicher

•

Poxviridae DNA virus

•

178 kbp genome, recombinant MVA with >30kbp
insert can be generated.

•

FDA approved smallpox vaccine

•

Replication-deficient in human. Strong immune
response

•

Promising viral vector against infection pathogens
and cancers

•

Titration method mainly based on infectious titer

•

Not thermolabile (stable over 24h, 37°C in culture)

1. Modified Vaccinia virus Ankara
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Vaccines and gene therapy challenges

•

•

FDA: Technique to modify a person’s
gene to cure disease

• Two deliveries: Direct and cell-based
• Efficient and safe vaccine/gene therapy design
• Scalable (scale: multi billion doses), low-cost and•rapid
vaccinevectors:
production
Different
viral vector, naked /
Scalable (multiple clinical trials, need for high titer doses) and low-cost
gene
therapy
production
plasmid DNA, lipofection
•

Gwendal Gränicher

1. Modified Vaccinia virus Ankara

Targeted diseases in clinical trials:
mainly cancer and monogenic
diseases.
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Traditional and modern MVA production
Chicken embryo fibroblastbased + MVA

Suspension avian cell line +
MVA

AGE1.CR.pIX cells +
MVA.CR19 (adapted virus)

+ Well established, relatively inexpensive
+ Scalable, chemically defined media, immortalized cell lines
- Poorly scalable, limited production capacity, - Need of cell aggregation,
…..time consuming, not immortalized cells
Gwendal Gränicher

…..Intracellular virus

1. Modified Vaccinia virus Ankara
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Approaches to intensify USP

•
•

Chicken embryo fibroblast
Avian suspension cell lines

Gwendal Gränicher

Cell line

Cell culture
mode

Cell culture
media

Process
Equipment

2. USP process intensification

•

Batch/perfusion/continuous
mode evaluation

•

Cell retention devices
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Perfusion mode cell culture

•

Production timeline
Footprint
Costs

Perfusion

Virus titer

Cell density

Batch

Flexibility

•
•
•

•

Process intensification: Higher production yield
with same footprint.
• Option 1: Perfusion mode
• Option 2: Two-stage continuous mode

•

Widely accepted for rec. protein production.
For virus production: mostly in academia.

Cell culture time
Gwendal Gränicher

2. USP process intensification
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Continuous cell culture

•

Production timeline
Footprint
Costs

Two-stage continuous
Total virus produced

Perfusion

Cell density

Batch

Flexibility

•
•
•

•

Process intensification: higher production yield
with same footprint
• Option 1: Perfusion mode.
• Option 2: Two-stage continuous mode

Cell culture time
Gwendal Gränicher

1. Introduction
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Evaluation of cell culture modes
•

Gather data on the MVA production yields to select the best production mode.

(Duck cell line)

MVA.CR19

AGE1.CR.pIX cells

HFBR, Hollow-fiber bioreactor; SF, Shake flask; STR-ATF, Stirred tank bioreactor with an alternating tangential flow filtration;
OSB, orbitally shaken bioreactor; SF, shaker flask.
Gwendal Gränicher

2. USP process intensification
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Evaluation of cell culture modes
•
Highest productivity using optimized perfusion
systems, TCID50 titration

Approach: Consecutive runs, determine amount of
virus produced over 3 months with same footprint.
Same virus strain and host cell line.

→ Optimized perfusion + HFBR, better results
→ Perfusion more scalable than HFBR
→ Higher cell concentration beneficial

Gwendal Gränicher

2. USP process intensification
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Perfusion culture: Approach for robust process integration
•

•

Acoustic settler
• Continuous harvesting

Capacitance sensor
• Automatization
• Increased robustness

•

USP-DSP integration
• Host cell DNA digestion
• Filtration
• Chromatography

MVA.CR19-GFP

Granicher et al, Biotechnology and Bioengineering, 2021
Gwendal Gränicher

3. Process integration
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Lab implementation

B2
B1

Gwendal Gränicher

3. Process integration

B3

B4
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Process equipment: Scalable continuous harvesting

@25E+06 cells/mL

•
•

@50E+06 cells/mL
AS3
AS4
ATF1

Similar performance for the AS and IS
Continuous harvesting: potentially lower virus degradation

•

Continuous harvesting also possible
with an ATF (PE, cutoff 10um)
AS, acoustic settler; IS, inclined settler

Gwendal Gränicher

3. Process integration

13

Production yields – 1L scale
Integrated perfusion vs batch: Same recovery,
4-fold yield increase (with DSP).
AGE1.CR.pIX

MVA.CR19-GFP

Integrated batch (n=3)
Integrated perfusion AS1

Perfusion: 3.8-8.5 fold Virtot increase
TCID50 titration, +19.4/-16.3%

Konstantinov et al 2015

Perfusion AS1
Perfusion AS2
Batch (n=3)

@25E+06cells/mL
@25E+06cells/mL
@2E+06cells/mL

Perfusion 2: No feeding automation
Gwendal Gränicher

Perfusion rate during virus harvesting: 1.5 BV/day
3. Process integration
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Product quality: Integrated batch vs perfusion
Robust integrated process

Integrated batch (n=3)
Integrated perfusion AS1

•
•
•

•
•
•
•

Similar host cell DNA and total protein
level per dose.
Host cell DNA <10 ng DNA/dose
1 dose = 108 pfu

First time successful implementation of integrated viral vector production.
Reduced footprint with the integrated perfusion.
Robust perfusion important
Eluate purity high enough for injection (although dose-dependent).

Gwendal Gränicher

3. Process integration
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Robust manufacturing with online capacitance probe

Cell growth phase

√

Automated perfusion
(50 pL/cell/day)

Gwendal Gränicher

Virus production phase

√

Online capacitance probe defines: Starting time of
…..continuous virus purification (10.6h after max. cell density).
3. Process integration
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Continuous DNA digestion and filtration
•
•
•
•
•

Primarily clarification acoustic settler
Continuous addition of 700mM salt mixture as a chaotropic agent
Coiled tubing (PFR) for 4h RT at 37°C (0.25 BV) allows >3 log host cell DNA depletion
2-step filtration with poly-propylene and cellulose acetate material
Primary filter: capacity = 240 L/m2 ; flow = 5.5 LMH

→ OPEX reduction for clarification with acoustic settler
→ Continuous DNA digestion reduces the hold-up volume (3.5 BV harvested in total)
→ Need of salt tolerant Endonuclease
→ Low filtration rate (<10 LMH): Inert material needed, low flow rate eventually increases filtration
capacity
Gwendal Gränicher

3. Process integration
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Semi-continuous chromatography
Steric exclusion chromatography
•
•
•

Size selectivity
Molecular crowding on
hydrophilic matrix using PEG
Membrane-based

Marichal-Gallardo et al 2018

Dynamic binding capacity = 1.8E+10 TCID50/mL
Loading: 30-76% (45mL material/2mL column)
40min / cycle
→ Membrane-based chromatography allows semi-continuous purification with simple bind-elutes
→ Need: Chromatography allowing a high yield with variable loading
Gwendal Gränicher

3. Process integration
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Economic analysis approach
Cost per dose

Process modelling

1L scale - experimental data
•

•

•

Inputs
Media, gas, filters, power,
water,…

•

Outputs
Virus, waste, gas,…

•

Infrastructure
Bioreactor, mixers, filter
holder, chromatography,…

•

Labor costs

Integrated perfusion

Integrated batch

Costs analysis,
scale-up,
Bottleneck
identification

SuperPro Designer Software

Gwendal Gränicher

4. Economic analysis

19

Economic analysis – 1L scale
Cost per dose

2.8-fold decreased cost per dose with perfusion mode
1L scale: OPEX increase for
perfusion from labor costs

Main consumables costs: Media
and endonuclease

Costly process steps: Seed train
and bioreactor production
Batch
Perfusion

Gwendal Gränicher

4. Process integration
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Cost per dose – case study
Target: 8 million MVA virus dose (1 dose = 108 PFU)
Batch

Perfusion

Run / year

53

36

Bioreactor Vw [L]

200

50

Main DSP equipment

Acoustic settler 200L scale
Filtration 1.47m2 + 1.12m2
Surge tanks 1x45L
Chromatography pilot scale

Acoustic settler 200L scale
Filtration 0.60m2 + 0.51m2
Plug flow reactor 12L
Surge tanks: 3x3L + 1x10L
Chromatography pilot scale

Culture media / year [L/y]

10,600

11,900

Buffer / year [L/y]

64,500

34,800

Filters / year [m2/y]

135

35

Endonuclease [kU/y]

370,000

440,000

Seed virus [mg/y]

8 ( about 7,100 doses)

16 (about 14,200 doses)

Seed cell [mg/y]

1,539,928

265,136

Gwendal Gränicher

4. Economic analysis
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Cost per dose – case study

•
•
•

Process

Cost per dose
[$/1k_dose]

200L batch mode

779.65

50L perfusion mode

758.58

Production
[doses/year]

8 million

Labor costs increase in perfusion mode (+61%) → need for automation
Moderate CAPEX decrease in perfusion mode (-20%) → due to extra equipment (ex: PFR)
>4-fold STY increase needed for perfusion vs batch.

OPEX, operating expense; CAPEX, capital expenditure.
Gwendal Gränicher

4. Economic analysis
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Conclusion and Outlook
•

Most efficient cell culture mode for virus: Perfusion mode.

•

Implementation of 1L integrated suspension cell culture in perfusion for viral vectors.

•

4-fold space-time yield reduction when integrated perfusion process.

•

Online capacitance probe could decrease costs through automation and high process robustness.

•

Cost efficiency for perfusion (vs batch) at least when already limited by bioreactor.
STY should be >4-fold higher.

→ Testing of a continuous production platform for other viral vectors such as AAV and lentivirus

Gwendal Gränicher

5. Conclusion and Outlook
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